173 related articles for article (PubMed ID: 36773034)
1. Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma.
Burkett WC; Zhao Z; Newton MA; Sun W; Deng B; Secord AA; Zhou C; Bae-Jump V
Ann Med; 2023 Dec; 55(1):603-614. PubMed ID: 36773034
[TBL] [Abstract][Full Text] [Related]
2. Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancer.
Buckingham L; Hao T; O'Donnell J; Zhao Z; Zhang X; Fan Y; Sun W; Zhang Y; Suo H; Secord AA; Zhou C; Bae-Jump V
Am J Cancer Res; 2022; 12(6):2850-2862. PubMed ID: 35812065
[TBL] [Abstract][Full Text] [Related]
3. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985
[TBL] [Abstract][Full Text] [Related]
4. Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer
O'Donnell J; Zhao Z; Buckingham L; Hao T; Suo H; Zhang X; Fan Y; John C; Deng B; Shen X; Sun W; Secord AA; Zhou C; Bae-Jump VL
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503790
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
Castellano GM; Zeeshan S; Garbuzenko OB; Sabaawy HE; Malhotra J; Minko T; Pine SR
Mol Cancer Ther; 2022 Sep; 21(9):1381-1392. PubMed ID: 35732569
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Hayes MP; Douglas W; Ellenson LH
Gynecol Oncol; 2009 Jun; 113(3):370-3. PubMed ID: 19272638
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
8. High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
Shen X; Wang J; Deng B; Chen S; John C; Zhao Z; Sinha N; Haag J; Sun W; Kong W; Spasojevic I; Batinic-Haberle I; Secord AA; Zhou C; Bae-Jump VL
Gynecol Oncol; 2024 Mar; 183():93-102. PubMed ID: 38555710
[TBL] [Abstract][Full Text] [Related]
9. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
10. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
[TBL] [Abstract][Full Text] [Related]
11. Early stage uterine serous carcinoma: management updates and genomic advances.
Fader AN; Santin AD; Gehrig PA
Gynecol Oncol; 2013 Apr; 129(1):244-50. PubMed ID: 23321062
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
Black JD; English DP; Roque DM; Santin AD
Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of Carboplatin plus Taxane Chemotherapy for Advanced or Recurrent Uterine Serous Carcinoma].
Matsuura T; Otsuka I
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1401-1404. PubMed ID: 27899784
[TBL] [Abstract][Full Text] [Related]
14. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
Chen S; Yao L
Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
[TBL] [Abstract][Full Text] [Related]
15. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
16. Ryanodine receptor 1-mediated Ca
Zhang L; Au-Yeung CL; Huang C; Yeung TL; Ferri-Borgogno S; Lawson BC; Kwan SY; Yin Z; Wong ST; Thomas V; Lu KH; Yip KP; Sham JSK; Mok SC
J Exp Clin Cancer Res; 2022 Aug; 41(1):242. PubMed ID: 35953818
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
18. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
Zeng X; Baba T; Hamanishi J; Matsumura N; Kharma B; Mise Y; Abiko K; Yamaguchi K; Horikawa N; Hunstman DG; Mulati K; Kitamura S; Taki M; Murakami R; Hosoe Y; Mandai M
Int J Cancer; 2019 Sep; 145(6):1635-1647. PubMed ID: 31228268
[TBL] [Abstract][Full Text] [Related]
20. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
